GSK plc 6-K, filed Jun 28, 2022
GSK plc (GSK)
6-K
2022-06-28
For: 2022-06-28
View Original
Added on
July 04, 2026
About this 6-K
GSK plc filed this 6-K on June 28, 2022.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR
15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the
month of June 2022
Commission
File Number 001-15170
GSK plc
(Translation
of registrant's name into English)
980 Great West Road, Brentford, Middlesex, TW8 9GS
(Address
of principal executive office)
Indicate
by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.
Form
20-F . . . .X. . . . Form 40-F . . . . . . . .
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(1): ____
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(7): ____
Issued: 28 June 2022, London UK
Japan's Ministry of Health, Labour and
Welfare accepts Shingrix regulatory submission to prevent shingles in
at-risk adults aged 18 years and older
●
Regulatory
submission aims to expand the number of people who can be protected
against shingles, including those with immunodeficiency or
immunosuppression
●
Shingrix is
already approved in Japan for adults aged 50 years and
above
GSK plc (LSE/NYSE: GSK) today announced the submission of a
regulatory application to the Japanese Ministry of Health, Labour
and Welfare (MHLW) for Shingrix (Zoster Vaccine Recombinant, Adjuvanted) for
the prevention of shingles (herpes zoster) in adults aged 18 years
and older who are at increased risk. This includes individuals with
immunodeficiency or immunosuppression caused by known disease or
therapy. Immunocompromised individuals are at greater risk of
shingles and associated complications than immunocompetent
individuals.[i]
Shingrix, a non-live,
recombinant sub-unit adjuvanted vaccine given intramuscularly in
two doses, was initially approved in 2018 by the Japanese MHLW to
prevent shingles in adults aged 50 years or
older.
The MHLW regulatory submission is based on six clinical trials in
patients aged 18 years and older who had undergone recent
blood-forming cells (stem cell) transplantation, kidney transplant,
or have blood cancer, solid tumour or HIV.[ii],[iii],[iv],[v],[vi],[vii]
In Japan, adults aged 18 years and older who are immunocompromised
or have chronic medical conditions have a higher incidence of
shingles, including a higher risk of developing associated
complications such as post-herpetic neuralgia (PHN), a severe
intermittent or continuous long-term nerve pain that occurs in
areas of skin previously affected by shingles. In a retrospective
cohort study using data from Japanese adults aged 18 years and
older, the risk of shingles was higher in women, irrespective of
age and increased with age.[viii]
About Shingles
Shingles, also known as herpes zoster, is caused by a reactivation
of the varicella-zoster virus (VZV) - the same virus that causes
chickenpox - which lays dormant in the body after the initial
infection. Natural age-related decline of the immune system can
allow VZV to resurface, causing shingles. People with a suppressed
or compromised immune system are also at increased risk of
developing shingles.i Globally,
over 90% of adults aged 50 years and older are infected with VZV
and are at risk of developing shingles.[ix] Approximately
600,000 new cases of shingles are reported in Japan each
year.[x]
About Shingrix
Shingrix is
a non-live, recombinant sub-unit vaccine approved by the Japanese
MHLW on 23 March 2018 to prevent shingles in adults 50 years and
older.
It combines an antigen, glycoprotein E, and an adjuvant system,
AS01B, to generate a VZV-specific immune response that can help
overcome the decline in VZV immunity as people age. The recombinant
shingles vaccine is not indicated to prevent primary varicella
infection (chickenpox).
In adults 50 years and older, the vaccine is intended to be
administered in two doses, two to six months apart. However, for
adults 18 years and older who are immunodeficient, immunosuppressed
or likely to become immunosuppressed due to known disease or
therapy and who would benefit from a shorter vaccination schedule,
the second dose can be administered one to two months after the
first dose in countries where the indication for this population
has been approved.
The European Commission and the United Kingdom
approved Shingrix on 25 August 2020 to prevent shingles and
PHN in adults aged 18 or older at increased risk of shingles. On 26
July 2021, the US Food and Drug Administration approved the vaccine
to prevent shingles in adults aged 18 years or older at increased
risk of shingles due to immunodeficiency or immunosuppression
caused by known disease or therapy. The extended indication for
preventing shingles and PHN in adults aged 18 years or older at
increased risk of developing shingles has also recently been
approved in Australia.
Shingrix is
also recommended in the US by the US Centers for Disease Control
and Prevention's Advisory Committee on Immunization Practices as
the preferred vaccine for the prevention of shingles and related
complications for immunocompetent adults aged 50 years and
older.[xi]
About GSK
GSK is a science-led global healthcare company. For further
information, please visit www.gsk.com/about-us.
|
GSK enquiries:
|
|
|
|
|
Media
enquiries:
|
Tim
Foley
|
+44 (0)
20 8047 5502
|
(London)
|
|
|
Simon
Moore
|
+44 (0)
20 8047 5502
|
(London)
|
|
|
Jack
Riley
|
+44 (0)
20 8047 5502
|
(London)
|
|
|
Kathleen
Quinn
|
+1 202
603 5003
|
(Washington
DC)
|
|
Analyst/Investor
enquiries:
|
Nick
Stone
|
+44 (0)
7717 618834
|
(London)
|
|
|
Sonya
Ghobrial
|
+44 (0)
7392 784784
|
(Consumer)
|
|
|
James
Dodwell
|
+44 (0)
20 8047 2406
|
(London)
|
|
|
Mick
Readey
|
+44 (0)
7990 339653
|
(London)
|
|
|
Josh
Williams
|
+44 (0)
7385 415719
|
(London)
|
|
|
Jeff
McLaughlin
|
+1 215
751 7002
|
(Philadelphia)
|
Cautionary statement regarding forward-looking
statements
GSK
cautions investors that any forward-looking statements or
projections made by GSK, including those made in this announcement,
are subject to risks and uncertainties that may cause actual
results to differ materially from those projected. Such factors
include, but are not limited to, those described in the Company's
Annual Report on Form 20-F for 2021, GSK's Q1 Results for 2022 and
any impacts of the COVID-19 pandemic.
Registered in England & Wales:
No.
3888792
Registered Office:
980
Great West Road
Brentford,
Middlesex
TW8
9GS
References
[i] Mueller,
NH et al. Varicella Zoster Virus Infection: Clinical Features,
Molecular Pathogenesis of Disease and Latency. Neurologic
Clinics, 2008; 26;675-697.
[ii] Bastidas
A, et al. JAMA 2019;132:123-133.
[iii] Berkowitz
EM, et al. J Infect Dis 2015;211:1279-1287.
[iv] Vink
P, et al. Cancer 2019;125:1301-1312.
[v] Dagnew
AF, et al. Lancet Infect Dis 2019;19:988-1000.
[vi] Vink
P, et al. Cancer 2019;125:1301-1312.
[vii] Stadtmauer
E, et al. Blood. 2014;124(19):2921-2929
[viii] Imafuku
S et al. Risk of herpes zoster in the Japanese population
with
immunocompromising and chronic disease conditions: Results from a
claims database cohort study, from 2005 to 2014. Journal of
Dermatology. 2020. ; 47: 236-244.
[ix] Bricout
H et al. "Herpes zoster-associated mortality in Europe: a
systematic review." BMC Public Health 15:466 (2015). Available at:
https://doi.org/10.1186/s12889-015-1753-y Last accessed: June
2022.
[x] Gnann
et al. Clinical practice. Herpes
zoster. N Eng J
Med. 2002;347(5):340-6
[xi] Dooling
KL et al. Recommendations of the Advisory Committee on Immunization
Practices for Use of Herpes Zoster Vaccines. CDC. 2018.
67(3);103-108.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorised.
|
|
GSK plc
|
|
|
(Registrant)
|
|
|
|
|
Date: June
28, 2022
|
|
|
|
|
|
|
By:/s/ VICTORIA
WHYTE
--------------------------
|
|
|
|
|
|
Victoria Whyte
|
|
|
Authorised
Signatory for and on
|
|
|
behalf
of GSK plc
|